Vir Biotechnology (VIR) Institutional Ownership

65.32% of Vir Biotechnology's stock is owned by institutional investors. Learn more on VIR's institutional investor holdings.

Of the 194 institutional investors that purchased Vir Biotechnology's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: ARCH Venture Management LLC ($25.61M), BlackRock Inc. ($20.68M), GSK plc ($8.55M), ADAR1 Capital Management LLC ($5.39M), State Street Corp ($1.52M), Pictet Asset Management Holding SA ($1.47M), and Balyasny Asset Management L.P. ($1.40M).

Institutional investors have bought a total of 63,111,826 shares in the last 24 months. This purchase volume represents approximately $565.98M in transactions.

Of the 73 institutional investors that sold Vir Biotechnology's stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: SB Investment Advisers UK Ltd. ($5.74M), Royal Bank of Canada ($711.64K), Vanguard Group Inc. ($678.12K), Renaissance Technologies LLC ($552.64K), Dimensional Fund Advisors LP ($471.68K), Millennium Management LLC ($393.90K), and Schroder Investment Management Group ($384.14K).

Institutional investors have sold a total of 12,105,820 shares in the last 24 months. This volume of shares sold represents approximately $78.95M in transactions.